NCT01695473 2021-01-13
Neoadjuvant BKM120 in High-risk Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
Clinical Trials
9 trialsNCT01629615 2020-10-28
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01349660 2020-06-17
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT01339052 2019-03-19
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01487265 2019-03-06
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02303041 2019-01-29
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Stanford University
Phase 2 Terminated
NCT01790932 2019-01-23
BKM120 For Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02301364 2017-10-19
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01385293 2017-05-19
BKM120 in Metastatic Castration-resistant Prostate Cancer
Duke University
Phase 2 Terminated